Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | unspecified PD-L1 antibody |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF mutant | lung non-small cell carcinoma | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD). | detail... |
| ARID1A mutant | endometrial cancer | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (4.6 vs 3.0 months, p=0.02) in patients with ARID1A-altered (n=10) endometrial cancer than in patients with ARID1A wild-type (n=13) tumors (PMID: 32111729). | 32111729 |
| ARID1A mutant | lung non-small cell carcinoma | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer but not statistically significant median progression-free survival (8.7 vs 4.6 months, p=0.53) in patients with ARID1A-altered (n=7) non-small cell lung cancer than in patients with ARID1A wild-type (n=104) tumors (PMID: 32111729). | 32111729 |
| KEAP1 mut STK11 mut | lung adenocarcinoma | not predictive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring both a KEAP1 mutation and STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 and wild-type STK11 when treated with an unspecified PD-L1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |
| ARID1A mutant | colorectal cancer | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (5.2 vs 2.1 months, p=0.005) in patients with ARID1A-altered (n=12) colorectal cancer than in patients with ARID1A wild-type (n=37) tumors (PMID: 32111729). | 32111729 |
| ARID1A loss | ovarian cancer | predicted - sensitive | unspecified PD-L1 antibody | Preclinical | Actionable | In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026). | 29736026 |
| POLD1 mutant | Advanced Solid Tumor | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, immune checkpoint inhibitor (ICI) treatment, including CTLA4, PD-1, and PD-L1-targeting antibodies, resulted in prolonged overall survival (34 vs 18 months, p=0.004) in patients with advanced solid tumors harboring POLE or POLD1 mutations compared to wild-type patients, and POLE/POLD1 mutation served as a predictor of response to ICI (p=0.047, HR=1.41) independent of MSI-H status (PMID: 31415061). | 31415061 |
| CTNNB1 act mut | hepatocellular carcinoma | decreased response | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in hepatocellular carcinoma patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without Wnt pathway mutations, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 mo vs. 7.4 mo) (PMID: 30373752; NCT01775072). | 30373752 |
| ARID1A mutant | Advanced Solid Tumor | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in significantly longer median progression-free survival (PFS, 11 vs 4 months, p=0.006) in patients with ARID1A-altered (n=46) tumors than in patients with ARID1A wild-type (n=329) tumors, and improved overall survival (31 vs 20 months, p=0.13), ARID1A alterations predicted longer PFS (HR=0.61, p=0.02) after immune checkpoint inhibitor therapies independent of MSI or TMB status (PMID: 32111729). | 32111729 |
| ARID1A mutant | gastroesophageal cancer | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (11.4 vs 2.5 months, p=0.21) in patients with ARID1A-altered (n=5) gastroesophageal cancer than in patients with ARID1A wild-type (n=16) tumors (PMID: 32111729). | 32111729 |
| PBRM1 mutant | lung non-small cell carcinoma | predicted - resistant | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, treatment with either an anti-PD-1 or anti-PD-L1 therapy resulted in a significantly shorter overall survival (p=0.0057) and progression-free survival (p=0.03) in patients with non-small cell lung cancer harboring a PBRM1 mutation compared to patients with wild-type PBRM1 (PMID: 36456601). | 36456601 |
| CD274 amp | Advanced Solid Tumor | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study | Actionable | In a clinical study, 66.7% (6/9) of advanced solid tumor patients harboring CD274 amplification demonstrated an objective response when treated with a PD-1/PD-L1 monotherapy (5 patients), a PD-1/PD-L1 therapy combined with an investigational drug (3 patients), or a combination of an anti-PD-1 and anti-CTLA4 therapy (1 patient) (PMID: 29902298). | 29902298 |
| ARID1A loss | colon cancer | predicted - sensitive | unspecified PD-L1 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026). | 29736026 |
| KEAP1 mutant | lung adenocarcinoma | not predictive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring a KEAP1 mutation demonstrated a shorter progression free survival compared to patients with wild-type KEAP1 when treated with an unspecified PD-L1 antibody, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |
| STK11 mutant | lung non-small cell carcinoma | decreased response | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, mutant STK11 correlated with a worse outcome with immune checkpoint inhibitor treatment compared to wild-type STK11 in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD). | detail... |
| ARID1A mutant | melanoma | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a retrospective analysis, anti-PD-1/PD-L1 therapies resulted in longer median progression-free survival (45.4 vs 3.0 months, p=0.08) in patients with ARID1A-altered (n=6) melanoma than in patients with ARID1A wild-type (n=91) tumors (PMID: 32111729). | 32111729 |
| B2M mutant | colorectal cancer | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, a cohort of colorectal cancer patients harboring B2M mutations demonstrated a clinical benefit of either a partial response or stable disease in 85% (11/13) when treated with a PD-1 or PD-L1 inhibitor (PMID: 31008436). | 31008436 |
| POLE mutant | Advanced Solid Tumor | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, immune checkpoint inhibitor (ICI) treatment, including CTLA4, PD-1, and PD-L1-targeting antibodies, resulted in prolonged overall survival (34 vs 18 months, p=0.004) in patients with advanced solid tumors harboring POLE or POLD1 mutations compared to wild-type patients, and POLE/POLD1 mutation served as a predictor of response to ICI (p=0.047, HR=1.41) independent of MSI-H status (PMID: 31415061). | 31415061 |
| STK11 mutant | lung adenocarcinoma | not predictive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, lung adenocarcinoma patients harboring an STK11 mutation demonstrated a shorter progression free survival compared to patients with wild-type STK11 when treated with an unspecified PD-L1 antibody treatment, but when compared to other treatments, all were associated with shorter progression free survival (PMID: 32312757). | 32312757 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04093323 | Phase II | alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod Ipilimumab unspecified PD-L1 antibody unspecified PD-1 antibody | Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma | Recruiting | USA | 0 |
| NCT02843165 | Phase II | unspecified PD-L1 antibody unspecified CTLA4 antibody unspecified PD-1 antibody | Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease | Active, not recruiting | USA | 0 |
CKB BOOST